Weekly Digest – October 2024 Weekly Digest – October 2024 14 Oct 2024: SystImmune, Inc. announces FDA clearance of IND application for BL-M11D1 in relapsed/refractory Acute Myeloid Leukemia SystImmune, Inc. announced that the FDA has cleared its IND application for […]
Weekly Digest – October 2024 Weekly Digest – October 2024 16 Oct 2024: BlissBio receives IND approval from FDA for novel ADC BB-1712 BlissBio’s investigational new drug application for BB-1712, an antibody-drug conjugate targeting B7-H3, has been approved by the […]
Weekly Digest – October 2024 Weekly Digest – October 2024 14 Oct 2024: ENHERTU approved in China as first HER2 directed therapy for patients with HER2 mutant metastatic non-small cell lung cancer Daiichi Sankyo and AstraZeneca’s ENHERTU has received conditional […]
